| Subject: | FDA Alerts Healthcare Providers to Precautions With Use Of The Drug Reminyl |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Thu, 7 Apr 2005 - 10:00 am |
| The FDA announced that Ortho-McNeil Neurologics, Inc. has modified the precautions component of the prescribing information for the medication Reminyl (galantamine hydrobromide) to indicate an incidence of deaths in patients with mild cogitative impairment taking the medication. Reminyl is a reversible, competitive acetylcholinesterase inhibitor used in the treatment of mild to moderate Alzheimer's disease. The reports of deaths were related to vascular causative factors such as CVA and MI;... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Related MCN Products:
|
|
With over 20 years experience in regulatory compliance, MCN Healthcare brings you the most comprehensive regulatory compliance tool available. StayAlert! is the only comprehensive e-mail notification service available that not only notifies you of the changes in major federal regulations, but also provides the policies, procedures, tools and best practices to help you meet the changing regulation. StayAlert! actively monitors TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others so you don't have to. Other vendors have components of legislated requirements available online or on CD-ROM. However there is no other product that marries regulatory agency mandates with implementation tools, making the latest compliance information immediately available online. No other product provides an interpretative analysis, followed by a practical application tool, therefore providing users with an immediate solution to compliance problems. StayAlert! includes operational components for healthcare organizations, allowing complete facility compliance with mandated requirements, online. |
|
